ISKJ | Fundamental Growth +30%
تم تحديثه
0. Top Russian Medical Genetic company
1. Develop alternative to Sputnik COVID-19 vacine named Betuvax-CoV-2
2. Russian Health Ministry approves clinical trails of Betuvax at September 27 2021. Clinical trails involve 116 volonteer without chronic diseases
3. Forecast release date midwinter 2021.
4. In case of anual vaccination of 1% Russian population target price: 120 RUB
5. In case of anu vaccination rate of 4%, target: 320 RUB
6. Govermental support rate up to +10-20% price impact
7. Lot's of other medical projects that support ISKJ fundamental price at 85 RUB without Betuvax project impact.
Target price: 125 RUB
1. Develop alternative to Sputnik COVID-19 vacine named Betuvax-CoV-2
2. Russian Health Ministry approves clinical trails of Betuvax at September 27 2021. Clinical trails involve 116 volonteer without chronic diseases
3. Forecast release date midwinter 2021.
4. In case of anual vaccination of 1% Russian population target price: 120 RUB
5. In case of anu vaccination rate of 4%, target: 320 RUB
6. Govermental support rate up to +10-20% price impact
7. Lot's of other medical projects that support ISKJ fundamental price at 85 RUB without Betuvax project impact.
Target price: 125 RUB
تم فتح الصفقة
Upside: 185 RUBSupply of Neovaskogulen product to the USA market
أغلقت الصفقة: تم الوصول للهدف
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.